|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM259735671 |
| 003 |
DE-627 |
| 005 |
20250220014201.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231224s2016 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2016.04.012
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n0865.xml
|
| 035 |
|
|
|a (DE-627)NLM259735671
|
| 035 |
|
|
|a (NLM)27114212
|
| 035 |
|
|
|a (PII)S1521-6616(16)30071-7
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Moya, Rosita
|e verfasserin
|4 aut
|
| 245 |
1 |
2 |
|a A pilot study showing associations between frequency of CD4(+) memory cell subsets at diagnosis and duration of partial remission in type 1 diabetes
|
| 264 |
|
1 |
|c 2016
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 30.03.2017
|
| 500 |
|
|
|a Date Revised 07.12.2022
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2016 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a In some patients with type 1 diabetes the dose of insulin required to achieve euglycemia is substantially reduced soon after diagnosis. This partial remission is associated with β-cell function and good glucose control. The purpose of this study was to assess whether frequencies of CD4(+) T cell subsets in children newly diagnosed with type 1 diabetes are associated with length of partial remission. We found that the frequency of CD4(+) memory cells, activated Treg cells and CD25(+) cells that express a high density of the IL-7 receptor, CD127 (CD127(hi)) are strongly associated with length of partial remission. Prediction of length of remission via Cox regression is significantly enhanced when CD25(+) CD127(hi) cell frequency is combined with either Insulin Dependent Adjusted A1c (IDAA1c), or glycosylated hemoglobin (HbA1c), or C-peptide levels at diagnosis. CD25(+) CD127(hi) cells do not express Foxp3, LAG-3 and CD49b, indicating that they are neither Treg nor Tr1 cells
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, N.I.H., Extramural
|
| 650 |
|
4 |
|a CD25(+) non-Treg
|
| 650 |
|
4 |
|a Partial remission
|
| 650 |
|
4 |
|a Regulatory cells
|
| 650 |
|
4 |
|a T cell subsets
|
| 650 |
|
4 |
|a Type 1 diabetes
|
| 650 |
|
7 |
|a C-Peptide
|2 NLM
|
| 650 |
|
7 |
|a FOXP3 protein, human
|2 NLM
|
| 650 |
|
7 |
|a Forkhead Transcription Factors
|2 NLM
|
| 650 |
|
7 |
|a Glycated Hemoglobin A
|2 NLM
|
| 650 |
|
7 |
|a Hypoglycemic Agents
|2 NLM
|
| 650 |
|
7 |
|a Insulin
|2 NLM
|
| 650 |
|
7 |
|a Integrin alpha2
|2 NLM
|
| 650 |
|
7 |
|a Interleukin-2 Receptor alpha Subunit
|2 NLM
|
| 650 |
|
7 |
|a Interleukin-7 Receptor alpha Subunit
|2 NLM
|
| 650 |
|
7 |
|a hemoglobin A1c protein, human
|2 NLM
|
| 700 |
1 |
|
|a Robertson, Hannah Kathryn
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Payne, Dawson
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Narsale, Aditi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Koziol, Jim
|e verfasserin
|4 aut
|
| 700 |
0 |
|
|a Type 1 Diabetes TrialNet Study Group
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Davies, Joanna Davida
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 166-167(2016) vom: 01. Mai, Seite 72-80
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:166-167
|g year:2016
|g day:01
|g month:05
|g pages:72-80
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2016.04.012
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 166-167
|j 2016
|b 01
|c 05
|h 72-80
|